IPO traction Omada just completed a Nasdaq listing and has a substantial funding base, signaling credibility and scalability potential for large employer, health plan, and government contract opportunities.

GLP-1 expansion Strategic partnerships with Lilly and integration with OptumRx open pathways to scale GLP-1 prescribing programs within employer benefits and pharmacy networks, presenting a strong upsell to benefits brokers.

Enterprise partnerships Existing model targets employers, health plans, PBMs, and government agencies; leverage these channels to pitch end-to-end chronic disease management programs as a cost-reduction and ROI driver for large accounts.

Profitability signal Announcement of a profitable quarter alongside a cash-pay option for GLP-1 medications enhances appeal to employers seeking predictable savings and to patients seeking accessible pricing.

Investor visibility Active investor relations activities and upcoming investor events create opportunities to benchmark value propositions, gather feedback, and accelerate expansion with potential financing support.